The success of Sildenafil initially sparked a surge for pharma, however recent shifts present a complicated picture for shareholders. Off-patent versions are eating into revenue, and ongoing patent challenges add https://phoebelkxb398579.sharebyblog.com/41061667/the-blue-pill-and-big-pharma-a-risky-bet